A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics
The influence of an antacid on droxicam pharmacokinetics was investigated in 12 healthy male volunteers. A two way cross-over study was performed after the oral administration of 20 mg of droxicam (Ombolan capsules) and droxicam together with an antacid (Mucal powder). The plasma concentrations of piroxicam, the active moiety of droxicam, were determined by a high-performance liquid chromatographic method. The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125.5 +/- 25.1 micrograms.h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h. Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h. These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1995 |
|---|---|
| Erschienen: |
1995 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
European journal of drug metabolism and pharmacokinetics - 20(1995), 4 vom: 06. Okt., Seite 275-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maya, M T [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 07.01.1997 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM089499816 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM089499816 | ||
| 003 | DE-627 | ||
| 005 | 20231222080148.0 | ||
| 007 | tu | ||
| 008 | 231222s1995 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0299.xml |
| 035 | |a (DE-627)NLM089499816 | ||
| 035 | |a (NLM)8983932 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maya, M T |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 07.01.1997 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The influence of an antacid on droxicam pharmacokinetics was investigated in 12 healthy male volunteers. A two way cross-over study was performed after the oral administration of 20 mg of droxicam (Ombolan capsules) and droxicam together with an antacid (Mucal powder). The plasma concentrations of piroxicam, the active moiety of droxicam, were determined by a high-performance liquid chromatographic method. The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125.5 +/- 25.1 micrograms.h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h. Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h. These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Aluminum Compounds |2 NLM | |
| 650 | 7 | |a Antacids |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Magnesium Compounds |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Silicates |2 NLM | |
| 650 | 7 | |a Piroxicam |2 NLM | |
| 650 | 7 | |a 13T4O6VMAM |2 NLM | |
| 650 | 7 | |a aluminum magnesium silicate |2 NLM | |
| 650 | 7 | |a 6M3P64V0NC |2 NLM | |
| 650 | 7 | |a droxicam |2 NLM | |
| 650 | 7 | |a F24ADO1E2D |2 NLM | |
| 700 | 1 | |a Pais, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Ruas Da Silva, J |e verfasserin |4 aut | |
| 700 | 1 | |a Morais, J A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of drug metabolism and pharmacokinetics |d 1980 |g 20(1995), 4 vom: 06. Okt., Seite 275-9 |w (DE-627)NLM000393231 |x 2107-0180 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:1995 |g number:4 |g day:06 |g month:10 |g pages:275-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 1995 |e 4 |b 06 |c 10 |h 275-9 | ||